Marblegate Acquisition Stock (NASDAQ: GATEU)

Marblegate Acquisition (NASDAQ:GATEU) Stock, Quote.Headers.trade-ideas

Marblegate Acquisition Corp is a blank check company.

Marblegate Acquisition Corp

Ladenburg Thalmann analyst Aydin Huseynov upgrades Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) from Neutral to Buy and announces $5 price target.

News

Upgrades

Price Target

Analyst Ratings

CMPX

Ladenburg Thalmann Upgrades Compass Therapeutics to Buy, Announces $5 Price Target

Mizuho analyst William Janela maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Outperform and lowers the price target from $59 to $50.

Mizuho Maintains Outperform on Murphy Oil, Lowers Price Target to $50

Mizuho analyst Nitin Kumar maintains Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) with a Neutral and lowers the price target from $210 to $194.

Mizuho Maintains Neutral on Hess, Lowers Price Target to $194

Ladenburg Thalmann analyst Aydin Huseynov upgrades Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) from Neutral to Buy and announces $16 price target.

ACRV

Ladenburg Thalmann Upgrades Acrivon Therapeutics to Buy, Announces $16 Price Target

WIIM

NTRA

Natera shares are trading higher after the company announced the publication of three peer-reviewed papers, resulting in over 85 peer-reviewed publications on its cancer diagnostic test Signatera

Mizuho analyst Nitin Kumar maintains Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) with a Outperform and lowers the price target from $205 to $189.

Mizuho Maintains Outperform on Chevron, Lowers Price Target to $189

Keybanc analyst Sophie Karp maintains Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) with a Overweight and raises the price target from $65 to $66.

Keybanc Maintains Overweight on Xcel Energy, Raises Price Target to $66

LifeSci Capital initiates coverage on Oruka Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) with a Outperform rating and announces Price Target of $41.

Initiation

ORKA

LifeSci Capital Initiates Coverage On Oruka Therapeutics with Outperform Rating, Announces Price Target of $41

Keybanc analyst Sophie Karp maintains WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) with a Overweight and raises the price target from $95 to $98.

Keybanc Maintains Overweight on WEC Energy Group, Raises Price Target to $98

Event To Feature Influential Speakers Discussing Commerce And Politics At Rosen Shingle Creek Resort

Politics

General

PSQH

PSQ Holdings Announces Robert F. Kennedy Jr. As Speaker For Inaugural Public Square Business Summit In Orlando On October 10-11, 2024

Mizuho analyst Nitin Kumar maintains ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) with a Neutral and lowers the price target from $132 to $129.

Mizuho Maintains Neutral on ConocoPhillips, Lowers Price Target to $129

UPST

Upstart shares are trading lower after the company announced a $300 million convertible senior notes due in 2029 in a private offering.

Keybanc analyst Brandon Nispel maintains T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) with a Overweight and raises the price target from $190 to $230.

TMUS

Keybanc Maintains Overweight on T-Mobile US, Raises Price Target to $230

Barclays analyst Julian Mitchell initiates coverage on GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Overweight rating and announces Price Target of $250.

Barclays Initiates Coverage On GE Vernova with Overweight Rating, Announces Price Target of $250

Mizuho analyst William Janela maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Underperform and lowers the price target from $35 to $28.

Mizuho Maintains Underperform on APA, Lowers Price Target to $28

ASND

Ascendis Pharma shares are trading higher after the company announced topline data from its pivotal approach trial of Transcon CNP (Navepegritide).

Mizuho analyst Nitin Kumar upgrades Delek US Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DK#NYSE">DK</a>) from Underperform to Neutral and lowers the price target from $28 to $26.

Mizuho Upgrades Delek US Hldgs to Neutral, Lowers Price Target to $26

JP Morgan analyst Jessica Fye upgrades BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) from Underweight to Neutral and raises the price target from $91 to $125.

BNTX

JP Morgan Upgrades BioNTech to Neutral, Raises Price Target to $125

While complex trading strategies are often associated with high profits, a recent Ether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) whale&#8217;s straightforward approach proves that simplicity can also <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40580243/crypto-trader-turns-5-000-into-millions-shares-key-insights-from-his-journey-looking-in-hi">yield substantial returns</a>.
What Happened: In February 2016, when Ether was trading at around $5 per token, an investor purchased 16,636 ETH through the crypto exchange ShapeShift, <a href="https://x.com/EmberCN/status/1835480135849607338">according</a> to Chinese crypto data account EmberCN.
The total cost at the time was approximately $87,006, with each token acquired at $5.23.
After holding the tokens for over eight years, the investor recently began selling off parts of their holdings. 
On Sep. 16, they sold 350 ETH at a price of $2,340 per token, yielding an impressive gain of $819,000—nearly ten times the original investment.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40875213/bitcoin-dips-below-59k-despite-436m-net-etf-inflows-last-week">Bitcoin Dips Below $59K Despite $436M Net ETF Inflows Last Week</a>
Despite the sale, the trader still holds over $38 million worth of ETH, demonstrating the power of a long-term buy-and-hold strategy in the volatile crypto market.
In contrast, more intricate trading strategies can also result in significant gains, as seen in the case of an NFT trader who acquired a $1.5 million <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40831680/cryptopunk-heist-1m-nft-snagged-for-18-000-in-smart-contract-exploit">CryptoPunk for just 10 ETH</a> (around $23,000).
This success story traces back to 2020 when fractional ownership of high-value digital assets gained popularity. CryptoPunk #2386, a rare Ape-themed NFT, was split into 10,000 shares among 257 owners on the now-defunct platform Niftex. 
In August 2024, a trader successfully acquired the full NFT by placing a &#8220;shotgun&#8221; bid using a smart contract, ultimately securing the asset despite resistance from other stakeholders.
Not all trading stories end on a positive note, however. 
On Sep. 14, blockchain analytics platform Lookonchain reported that James Fickel, a crypto millionaire and early ETH investor, lost $43 million in a bet that Bitcoin would rise faster than ETH. 
His unsuccessful wager added to his growing debt, which now totals $132 million, underscoring the risks involved in speculative trades.
What&#8217;s Next: The timing of these developments is crucial as Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19 approaches.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40874541/anthony-scaramucci-more-gop-officials-will-start-to-denounce-trump-senator-mitt-romney-may">Anthony Scaramucci: &#8216;More GOP Officials Will Start To Denounce Trump&#8217; — Senator Mitt Romney May Be One Of Them, Polymarket Traders Think</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

Ultra-Patient ETH Trader Turns $87K Into $38M: But Would You Have Waited 8 Years To Take Profits?

Mizuho analyst Anthony Crowdell upgrades Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) from Neutral to Outperform and raises the price target from $82 to $89.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Marblegate Acquisition

Marblegate Acquisition (GATEU) Forecast

Marblegate Acquisition (NASDAQ:GATEU) Stock, Quote.Headers.trade-ideas